hepat
complic
hepat
c
viru
hcv
includ
fibrosi
cirrhosi
acceler
human
immunodefici
viru
hiv
infect
individu
although
liver
biopsi
remain
gold
standard
stage
hcvassoci
liver
diseas
test
result
seriou
complic
subject
sampl
error
challeng
prompt
search
noninvas
method
liver
fibrosi
stage
end
compar
serum
proteom
profil
differ
stage
fibrosi
hivhcv
coand
hcv
monoinfect
patient
use
surfaceenhanc
laser
desorpt
ioniz
timeofflight
mass
spectrometri
selditof
ms
sera
hivhcv
coand
hcv
monoinfect
subject
stage
fibrosi
test
sera
fraction
randomli
appli
protein
chip
array
imac
spectra
gener
low
high
laser
intens
sixteen
biomark
achiev
p
valu
roc
valu
predict
fibrosi
statu
coinfect
individu
mono
infect
subject
five
candid
biomark
contribut
monoand
coinfect
subject
candid
diagnost
algorithm
creat
distinguish
nonfibrot
fibrot
individu
use
panel
biomark
peak
morbid
mortal
human
immunodefici
viru
hiv
infect
individu
significantli
decreas
due
effect
longterm
combin
antiretrovir
therapi
cart
new
complic
howev
emerg
key
issu
within
popul
hiv
hepat
c
viru
hcv
coinfect
instanc
affect
hivinfect
patient
develop
countri
although
impact
hcv
hiv
diseas
progress
minim
known
hiv
acceler
hcvrelat
liver
diseas
effect
hiv
hcv
infect
includ
higher
rate
viral
persist
increas
hcv
viral
load
vl
studi
shown
hcvassoci
liver
diseas
fibrosi
cirrhosi
end
stage
liver
diseas
esld
acceler
hivinfect
individu
mechan
underli
rapid
liver
diseas
progress
hivhcv
coinfect
patient
like
multifactori
present
complet
understood
hepat
fibrosi
result
deposit
scar
tissu
may
lead
cirrhosi
character
distort
liver
architectur
major
determin
morbid
mortal
patient
liver
diseas
mani
countri
degre
hepat
fibrosi
princip
determin
access
highli
efficaci
hcv
treatment
known
direct
act
antivir
liver
biopsi
remain
gold
standard
stage
hcvassoci
liver
diseas
howev
liver
biopsi
result
seriou
complic
costli
feasibl
repeat
serial
subject
sampl
error
problem
prompt
search
noninvas
method
liver
fibrosi
stage
fibroscan
transient
elastographi
technolog
base
assess
liver
stiff
sever
factor
limit
examin
morbid
obes
ascit
small
intercost
space
better
result
shown
patient
sever
fibrosi
safe
reliabl
simpl
altern
need
diagnos
monitor
fibrosi
caus
hcv
infect
proteom
fingerprint
diagnost
concept
base
idea
diseas
state
often
associ
distinct
configur
circul
protein
analysi
combin
sever
biomark
offer
possibl
enhanc
diagnost
accuraci
compar
individu
biomark
limit
diagnost
sensit
specif
surfaceenhanc
laser
desorpt
ionizationtimeofflight
mass
spectrometri
selditof
ms
offer
highthroughput
protein
profil
nativ
biolog
specimen
platform
success
use
discoveri
tool
biomark
associ
inflamm
cancer
human
infecti
diseas
selditof
ms
serum
profil
accur
distinguish
patient
differ
stage
liver
diseas
specif
associ
hcv
infect
rang
chronic
hepat
hcvassoci
hepatocellular
carcinoma
hcc
end
compar
serum
proteom
profil
differ
stage
fibrosi
hiv
hcv
coand
hcv
monoinfect
patient
use
selditof
ms
aim
identifi
proteom
fingerprint
could
use
develop
diagnost
test
detect
stage
liver
fibrosi
hivhcv
coinfect
individu
report
selditof
msbase
altern
assay
achiev
high
sensit
specif
detect
fibrosi
patient
hivhcn
coinfect
canadian
coinfect
cohort
studi
ccc
cihr
canadian
hiv
trial
network
prospect
multicentr
studi
recruit
hivhcv
coinfect
patient
centr
across
canada
sinc
approv
particip
research
ethic
board
describ
detail
elsewher
octob
patient
enrol
analysi
particip
select
base
avail
serum
specimen
within
one
year
liver
biopsi
hcv
monoinfect
patient
undergo
liver
biopsi
prospect
recruit
site
particip
ccc
serum
sampl
obtain
within
year
liver
biopsi
total
individu
studi
includ
hcv
monoinfect
hivhcv
coinfect
subject
patient
stage
fibrosi
stage
determin
liver
biopsi
select
analysi
serum
protein
fraction
prior
selditof
ms
analysi
describ
briefli
sampl
fraction
rehydr
q
hyperd
f
bead
ph
fraction
use
biorad
hercul
ca
serum
fraction
kit
follow
manufactur
instruct
step
protein
fraction
includ
bind
wash
perform
biomek
laboratori
autom
workstat
beckman
coulter
fullerton
ca
integr
micropl
shaker
micromix
diagnost
product
compani
lo
angel
ca
hold
array
bioprocessor
biorad
serum
fraction
store
analyz
qualiti
control
purpos
commerci
human
refer
sera
healthi
donor
valley
biomed
winchest
va
duplic
includ
test
run
sampl
random
within
across
array
blank
spot
includ
neg
control
appli
three
type
proteinchip
array
weak
cation
exchang
immobil
metal
affin
captur
hydrophobicreversephas
biorad
array
prepar
previous
describ
analyz
proteinchip
biolog
system
reader
seri
pc
use
proteinchip
softwar
version
biorad
preliminari
studi
data
shown
sampl
group
bound
onto
proteinchip
array
fraction
analyz
fraction
yield
satisfactori
result
ie
differenti
biomark
select
selditof
ms
analysi
fraction
ph
flow
ph
organ
analysi
array
optim
experi
array
led
similar
result
therefor
minim
cost
time
analysi
fraction
subject
ms
analysi
spot
read
lowand
highenergi
laser
intens
use
extern
calibr
standard
bovin
insulin
da
ubiquitin
da
cytochrom
c
da
da
horseradish
peroxidas
da
igg
da
spectra
subject
mass
calibr
base
set
use
collect
data
baselin
subtract
use
set
time
expect
peak
width
nois
subtract
da
lowenergi
da
highenergi
acquisit
data
normal
total
ion
current
either
low
intens
kda
high
intens
kda
use
extern
coeffici
spectra
normal
factor
doubl
mean
delet
analys
perform
two
step
first
autom
peak
detect
appli
use
cluster
featur
biomark
wizard
softwar
biorad
cluster
p
valu
mannwhitney
u
test
visual
inspect
follow
manual
peak
relabel
relabel
exact
p
valu
differ
averag
peak
intens
two
group
calcul
wilcoxon
exact
test
neg
popul
nomild
fibrosi
posit
popul
signific
fibrosi
peak
p
valu
receiv
oper
characterist
roc
valu
consid
potenti
biomark
biomark
pattern
softwar
biorad
analysi
appli
clean
cluster
data
program
use
supervis
pattern
classif
method
classif
regress
tree
cart
identifi
peak
greatest
contribut
discrimin
group
cart
procedur
seek
minim
cost
function
balanc
predict
error
either
sens
total
number
biomark
use
rel
import
peak
given
algorithm
measur
order
select
decis
tree
number
correct
predict
credit
similar
analysi
perform
find
discrimin
peak
four
stage
fibrosi
two
sampl
show
highest
intens
selditof
ms
analysi
biomark
select
posit
sampl
two
lowest
intens
select
neg
control
enrich
fraction
purifi
nupag
precast
gel
invitrogen
life
technolog
carlsbad
ca
v
min
tri
buffer
ph
stain
colloid
blue
invitrogen
band
interest
excis
ingel
digest
base
protocol
previous
describ
briefli
gelbound
protein
denatur
use
dithiothreitol
mm
mm
ammonium
bicarbon
min
alkyl
mm
mm
ammonium
bicarbon
min
digest
trypsin
ngml
mm
ammonium
bicarbon
acetonitril
overnight
tryptic
digest
extract
formic
acidacetonitrileisopropanolwat
time
acetonitril
time
vacuum
dri
dri
peptid
sampl
resuspend
trifluoroacet
acid
tfa
sonic
min
desalt
reversephas
ziptip
accord
manufactur
protocol
millipor
billerica
sampl
elut
acid
chca
matrix
mgml
tfa
water
solut
directli
spot
onto
ab
optitof
stainless
steel
plate
ab
sciex
framingham
allow
dri
room
temperatur
matrixassist
laser
desorpt
ioniz
timeofflight
mass
spectrometri
malditof
ms
data
acquir
plu
maldi
toftof
analyz
ab
sciex
seri
explor
softwar
intern
calibr
carri
use
monoisotop
mass
angiotensin
glu
fibrinopeptid
b
adrenocorticotrop
hormon
acth
fragment
positiveion
reflector
mode
ms
data
collect
mass
rang
da
use
fix
laser
intens
nj
shotsspectrum
uniformli
random
spot
search
pattern
ms
spectrum
abund
ms
peak
select
msm
use
acquisit
method
exclud
ion
sn
less
precursor
ion
strongest
sn
acquir
first
use
kv
msm
oper
mode
rel
precursor
mass
window
set
metast
suppress
enabl
msm
acquisit
select
precursor
set
shot
per
spectrum
shot
per
subspectrum
use
fix
laser
intens
nj
protein
identif
perform
proteinpilot
softwar
use
paragon
algorithm
ab
sciex
peptid
present
posit
sampl
absent
neg
sampl
select
msm
data
search
uniprotkbswissprot
databas
download
march
homo
sapien
hcv
hiv
trypsin
select
digest
enzym
search
paramet
includ
cystein
alkyl
iodoacetamid
gelbas
thorough
id
focu
biolog
modif
mass
spectrometri
proteom
data
deposit
proteomexchang
consortium
via
pride
partner
repositori
dataset
identifi
demograph
clinic
characterist
studi
popul
shown
tabl
coinfect
monoinfect
patient
similar
respect
except
higher
proport
report
recent
alcohol
use
vs
fewer
women
vs
among
coinfect
patient
coinfect
individu
gener
younger
mean
year
compar
monoinfect
mean
year
hcvinfect
shorter
period
time
vs
year
last
differ
would
expect
know
acceler
progress
fibrosi
coinfect
patient
group
divid
four
categori
accord
liver
biopsi
score
n
n
n
n
base
battsludwig
score
system
characterist
accord
fibrosi
score
also
shown
tabl
selditof
ms
approach
appli
sampl
patient
due
differ
paramet
age
durat
hcv
infect
hcv
monoinfect
hiv
hcv
coinfect
individu
spectra
group
analyz
separ
biomark
program
focu
singl
diseas
dichotom
pattern
ie
either
posit
neg
primari
comparison
nonfibrot
patient
advanc
fibrot
patient
due
rel
small
number
sampl
group
pool
group
togeth
analysi
use
biomark
wizard
softwar
sixteen
potenti
biomark
signific
intens
differ
good
area
curv
auc
roc
curv
analysi
identifi
tabl
six
individu
biomark
downregul
group
advanc
fibrosi
eight
upregul
moder
chang
two
group
test
abil
biomark
differenti
patient
regard
stage
liver
fibrosi
signific
intens
differ
p
valu
three
biomark
demonstr
signific
differ
express
k
mz
shown
fig
cumul
data
illustr
chang
multipl
protein
biomark
use
fingerprint
reflect
particular
diseas
state
similar
analysi
perform
hcv
monoinfect
sampl
fourteen
classifi
signific
intens
differ
identifi
tabl
repres
seldim
spectra
identifi
biomark
found
fig
seldi
tof
ms
peak
valu
avail
file
select
biomark
greatest
discriminatori
power
distinguish
nonfibrot
fibrot
patient
biomark
pattern
recognit
softwar
use
gener
random
train
test
data
set
candid
decis
tree
coinfect
patient
biomark
k
mz
serv
main
splitter
highest
individu
predict
rate
use
build
algorithm
repres
decis
tree
achiev
sensit
specif
present
fig
massovercharg
mz
valu
mean
signal
intens
areaundercurv
auc
select
individu
differenti
express
peptidesprotein
hepat
fibrosi
fibrosi
fibrosi
esld
fibrosi
patient
biomark
pattern
base
cart
analysi
use
gener
candid
diagnost
algorithm
number
root
node
descend
node
termin
node
repres
mass
valu
follow
intens
valu
nonfibrot
individu
class
individu
signific
fibrosi
class
algorithm
abl
correctli
diagnos
individu
howev
algorithm
appli
hcv
monoinfect
sampl
obtain
accuraci
sensit
specif
data
shown
evalu
possibl
influenc
hiv
diseas
activ
biomark
assess
correl
biomark
marker
hiv
progress
hiv
rna
count
fig
highli
correl
one
anoth
fig
howev
unlik
biomark
specif
coinfect
abl
obtain
good
decis
tree
biomark
data
shown
presumpt
identif
base
peptid
present
posit
sampl
absent
neg
sampl
serum
fraction
run
sodium
dodecyl
sulfatedenatur
polyacrylamid
gel
electrophoresi
sdspage
select
band
cut
neg
control
tabl
summar
biomark
identifi
malditof
ms
compar
posit
neg
sampl
candid
biomark
host
origin
includ
immunoglobulin
ig
kappa
chain
constant
c
region
k
mz
haptoglobin
k
mz
alpha
chain
k
mz
possibl
truncat
form
apolipoprotein
k
mz
plasminogen
k
mz
serotransferrin
k
mz
use
marker
pattern
recognit
softwar
tri
establish
decis
tree
use
cluster
distinguish
fibrot
patient
healthi
individu
coinfect
obtain
algorithm
use
biomark
k
mz
algorithm
abl
correctli
diagnos
individu
sensit
specif
respect
fig
second
analysi
perform
individu
use
known
biomark
obtain
similar
result
effici
sensit
specif
howev
algorithm
four
node
use
biomark
k
mz
fig
date
new
biomark
fibrosi
sought
primarili
use
differenti
twodimension
gel
electrophoresi
separ
tissu
serum
togeth
mass
spectrometri
protein
identif
proteom
analysi
plasma
serum
deriv
hcvinfect
subject
emerg
techniqu
identif
biomark
indic
diseas
progress
sever
use
plasma
sampl
clinic
defin
patient
fibrosi
progress
biopsi
obtain
result
support
potenti
use
selditof
ms
profil
tool
follow
diseas
progress
use
selditof
ms
observ
chang
level
plasma
proteinspeptid
monoinfect
coinfect
progress
hepat
fibrosi
obtain
satisfactori
decis
tree
accuraci
identifi
nonfibrot
patient
compar
individu
signific
fibrosi
coinfect
sensit
specif
misclassifi
patient
algorithm
could
due
low
reliabl
biopsi
assign
diseas
stage
categoris
need
take
consider
refer
point
biopsi
test
done
within
year
sampl
collect
biopsi
subject
sampl
error
interobserv
variabl
aspir
aminotransferas
ast
platelet
ratio
index
apri
valid
surrog
marker
signific
hepat
fibrosi
hivhcv
coinfect
support
possibl
five
eight
coinfect
patient
misclassifi
selditof
ms
biomark
apri
valu
correl
biopsi
score
unfortun
unabl
gener
algorithm
could
accur
diagnos
monoand
coinfect
use
set
biomark
could
due
biolog
differ
infect
even
though
observ
phenotyp
liver
fibrosi
possibl
activ
liver
diseas
progress
differ
two
popul
sever
studi
report
coinfect
individu
progress
rapidli
esld
mono
infect
individu
therefor
possibl
biomark
observ
coinfect
fact
marker
acceler
fibrosi
differ
mono
coinfect
protein
fingerprint
observ
suggest
analys
might
shed
light
underli
patholog
mechan
acceler
liver
fibrosi
progress
among
hiv
posit
patient
could
achiev
care
match
sampl
test
import
covari
determin
risk
acceler
diseas
hcv
import
note
biomark
use
algorithm
hivhcv
coinfect
except
one
mz
correl
marker
hiv
diseas
progress
eg
hiv
rna
count
consequ
biomark
probabl
relat
liver
fibrosi
reflect
immun
respons
inflammatori
environ
present
diseas
import
emphas
even
though
detect
biomark
use
stage
liver
fibrosi
monoand
coinfect
individu
affirm
biomark
specif
hcvinduc
fibrosi
order
establish
specif
need
valid
algorithm
nonhcv
liver
anomali
alcohol
liver
diseas
hepat
binduc
fibrosi
hcc
like
sever
candid
biomark
gener
marker
liver
damag
sinc
liverderiv
alreadi
found
liver
infect
addit
observ
biomark
present
mono
coinfect
good
correl
lead
us
believ
potenti
identifi
biomark
would
abl
diagnos
fibrosi
independ
hiv
infect
statu
sever
noninvas
model
util
test
routin
avail
group
incorpor
routin
test
laboratori
data
assess
fibrosi
noninvas
tri
improv
algorithm
ad
apri
valu
without
success
data
shown
although
fibroscan
larg
replac
liver
biopsi
clinic
still
poor
overal
specif
lack
sensit
middl
stage
fibrosi
might
interest
evalu
potenti
incorpor
fibroscan
improv
accuraci
diagnost
algorithm
particularli
distinguish
middl
stage
fibrosi
emerg
field
msbase
protein
profil
bodi
fluid
profil
use
diagnos
diseas
extend
use
depend
identif
protein
discrimin
peak
howev
protein
identif
still
possibl
add
biolog
relev
find
abl
identifi
ig
kappa
chain
c
region
haptoglobin
serum
biomark
hivhcv
coinfect
decis
tree
differenti
nonfibrot
individu
individu
signific
fibrosi
hcvinfect
individu
use
known
biomark
biomark
pattern
base
cart
analysi
use
gener
candid
diagnost
algorithm
number
root
node
descend
node
termin
node
repres
mass
valu
cxxxxxx
follow
intens
valu
class
nonfibrot
individu
class
individu
signific
fibrosi
truncat
form
plasminogen
interest
observ
protein
alreadi
identifi
biomark
fibrosi
exampl
fibrotest
base
haptoglobin
macroglobulin
gamma
globulin
gamma
glutamyl
transferas
total
bilirubin
measur
serum
specimen
ig
kappa
c
region
known
good
biomark
inflamm
malign
predictor
nonhodgkin
lymphoma
patient
hiv
patient
hcv
data
demonstr
use
selditof
ms
technolog
could
stage
discret
level
liver
fibrosi
chang
intens
biomark
detect
even
use
peak
alreadi
known
marker
nt
abl
obtain
optim
algorithm
compar
unidentifi
peak
sera
use
studi
fraction
without
prior
deplet
abund
serum
protein
highabund
protein
mask
presenc
lowerabund
protein
either
host
viru
origin
ms
studi
identifi
biomark
prove
fragment
full
length
abund
protein
fragment
may
product
natur
cours
protein
degrad
associ
extent
andor
type
infect
futur
work
focu
identifi
less
abund
biomark
could
host
relat
viral
deriv
identif
viral
deriv
plasma
biomark
could
greatli
enhanc
specif
assay
biomark
identifi
hivhcv
mono
coinfect
individu
pote
ankyrin
domain
famili
member
e
histidinerich
glycoprotein
fibronectin
complement
similar
mass
biomark
discov
selditof
ms
would
interest
confirm
use
immunocaptur
assay
addit
yang
et
al
found
complement
interalphatrypsin
inhibit
heavi
chain
biomark
candid
predict
hepat
fibrosi
use
isobar
tag
rel
absolut
quantit
itraq
differenti
gel
electrophoresi
dige
author
also
found
ig
kappa
chain
c
region
haptoglobin
other
potenti
biomark
candid
howev
studi
includ
pool
serum
sampl
peopl
chronic
hcv
noninfect
individu
use
selditof
ms
serum
profil
schwelgl
et
al
found
biomark
k
mz
help
differenti
healthi
control
hcc
patient
studi
fraction
sampl
concentr
lowmass
protein
metalbind
affin
studi
differ
significantli
test
hcv
infect
individu
look
highand
lowmass
protein
fraction
sampl
use
differ
type
proteinchip
metal
bind
weak
cation
exchang
hydrophobicreversephas
unlik
previou
studi
use
selditof
ms
diagnos
diseas
infect
aim
evalu
progress
diseas
dichotom
posit
neg
outcom
expect
observ
either
absenc
presenc
specif
biomarkerspeak
rather
gradual
differ
plasma
level
certain
peptidesprotein
differ
stage
liver
fibrosi
would
interest
see
scale
biomark
ad
obtain
score
could
accomplish
better
correl
stage
liver
fibrosi
patient
ccc
studi
enrol
coinfect
individu
sinc
process
studi
longitudin
chang
biomark
coinfect
individu
progress
fibrosi
addit
wonder
biomark
may
vari
treatment
hcv
infect
shown
marker
noninvas
measur
liver
fibrosi
gain
accept
longterm
evalu
hepat
complic
hivhcv
coinfect
investig
serum
proteom
profil
hivhcv
coinfect
hcv
monoinfect
patient
selditof
ms
identif
biomark
may
also
give
uniqu
insight
complex
prolong
hostviru
interact
lead
liver
fibrosi
support
inform
tabl
selditof
